Thomas Eric Duncan, the first patient to be diagnosed with Ebola in the United States, is now receiving an experimental drug called brincidofovir, according to a statement from Texas Health Presbyterian Hospital Dallas. Duncan is currently in critical condition.
Brincidofovir, which is still in the experimental phase, was just approved by the FDA on Monday for use in patients with Ebola, according to a statement by biopharmaceutical company Chimerix. Test tube experiments have revealed that brincidofovir acts against Ebola in the same way the drug fights other viruses like adenovirus and smallpox, according to a statement from the company. Animal testing for Brincidofovir against Ebola is ongoing.
See this story on http://ift.tt/hFWySe
Posted by Unknown on Tuesday, October 7, 2014 - Rating: 4.5
0 comments "Dallas Ebola Patient Receives Experimental Drug"
Post a Comment